Loading…
The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population
Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example warfarin, in patients with non-valvular atrial fibrillation. Limited studies are available reporting a model with a good discriminative ability to predic...
Saved in:
Published in: | PloS one 2021-05, Vol.16 (5), p.e0250502-e0250502 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203 |
---|---|
cites | cdi_FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203 |
container_end_page | e0250502 |
container_issue | 5 |
container_start_page | e0250502 |
container_title | PloS one |
container_volume | 16 |
creator | AlAmmari, Maha Sultana, Khizra Alturaiki, Abdulrahman Thomas, Abin AlBabtain, Monirah AlAyoubi, Fakahr Richi, Hanie |
description | Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example warfarin, in patients with non-valvular atrial fibrillation. Limited studies are available reporting a model with a good discriminative ability to predict the bleeding risk score when using direct oral anticoagulants.
Patient data were collected from King Abdulaziz Medical City, King Fahad Cardiac Center, and Prince Sultan Cardiac Center in Riyadh, from outpatients, inpatients, or primary care clinics. In total, 1722 patients with a prescription for a new oral anticoagulant, Dabigatran, Rivaroxaban, or Apixaban, were enrolled. A resampling approach for variable selection was used and a five-fold cross-validation to assess the model fit and misclassification probabilities. The analysis used the receiver operating characteristics curve (ROC) and the concordance (c) statistic to assess the validation models' discriminative power. The final penalized likelihood parameters were used for the development of the risk prediction tool. The accuracy of a classification and the prediction are reported with the sensitivity, specificity, and Brier score.
Bleeding occurred in 11.15% of cases, of which 23.08% required a blood transfusion and 51.65% had a reduction in haemoglobin of more than 2 gm. The variable selection model identified 15 predictors associated with major bleeding. The discriminative ability of the model was good (c-statistic 0.75, p = 0.035). The Brier score of the model was 0.095. With a fixed cut-off probability value of 0.12 for the logistic regression equation, the sensitivity was 72.7%, and the specificity 66.3%.
This model demonstrated a good performance in predicting the bleeding risk in Arab patients treated with novel oral anticoagulants. This easy to use bleeding risk score will allow the clinician to quickly classify patients according to their risk category, supporting close monitoring and follow-up for high-risk patients, without laboratory and radiological monitoring. |
doi_str_mv | 10.1371/journal.pone.0250502 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d24042cc595e49cba87a98f23a2bdac4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A660540984</galeid><doaj_id>oai_doaj_org_article_d24042cc595e49cba87a98f23a2bdac4</doaj_id><sourcerecordid>A660540984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203</originalsourceid><addsrcrecordid>eNqNk9-K1DAUxoso7rr6BiIBQfRixjRp2uZGWBb_LCws6OptOE2TmYxp0k3SUR_Q9zLdGZcZ8EJ60Sbn-345PeEriuclXpa0Kd9u_BQc2OXonVpiwjDD5EFxWnJKFjXB9OHB90nxJMYNxoy2df24OKGUU94Qflr8vlkr1Kutsn4clEsIXI-2YE0PyXiHvEaAhskms4VgoLMKDb5XFiWPxqB6IxNKGZELeeFWKJj4HUXpg0LaBzRmTMZG9MOkNXLeLTJ8O1kICFIGWqRNF4y1u-OmODN6E1Tm-pDL4JKRHlbZMmOMuzvuPECHRj9OO9_T4pEGG9Wz_fus-Prh_c3Fp8XV9cfLi_OrhawrnBatpMDriuuuLVnTtnXDaq4Za3pdQ61xp0rdY8Ykl7rRtKYKZEs5aSXDjcxzPCsud9zew0aMwQwQfgkPRtxt-LASEHK_VomeVLgiUjLOVMVlB20DvNWEAul6kFVmvduxxqkbVC_zlPL_HkGPK86sxcpvRYs5aVibAa_3gOBvJxWTGEyUKo_SKT9FQRghJWekabL05U66gtyacdpnopzl4ryuMaswb-eOlv9Q5adXQ74Dp7TJ-0eGN0eGrEnqZ1rBFKO4_PL5_7XX3461rw60awU2raO303zV8VhY7YQy-BiD0vfjK7GYUyL2KRFzSsQ-Jdn24nD096a_saB_AKM-FD4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522195277</pqid></control><display><type>article</type><title>The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>AlAmmari, Maha ; Sultana, Khizra ; Alturaiki, Abdulrahman ; Thomas, Abin ; AlBabtain, Monirah ; AlAyoubi, Fakahr ; Richi, Hanie</creator><contributor>Nagler, Michael</contributor><creatorcontrib>AlAmmari, Maha ; Sultana, Khizra ; Alturaiki, Abdulrahman ; Thomas, Abin ; AlBabtain, Monirah ; AlAyoubi, Fakahr ; Richi, Hanie ; Nagler, Michael</creatorcontrib><description>Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example warfarin, in patients with non-valvular atrial fibrillation. Limited studies are available reporting a model with a good discriminative ability to predict the bleeding risk score when using direct oral anticoagulants.
Patient data were collected from King Abdulaziz Medical City, King Fahad Cardiac Center, and Prince Sultan Cardiac Center in Riyadh, from outpatients, inpatients, or primary care clinics. In total, 1722 patients with a prescription for a new oral anticoagulant, Dabigatran, Rivaroxaban, or Apixaban, were enrolled. A resampling approach for variable selection was used and a five-fold cross-validation to assess the model fit and misclassification probabilities. The analysis used the receiver operating characteristics curve (ROC) and the concordance (c) statistic to assess the validation models' discriminative power. The final penalized likelihood parameters were used for the development of the risk prediction tool. The accuracy of a classification and the prediction are reported with the sensitivity, specificity, and Brier score.
Bleeding occurred in 11.15% of cases, of which 23.08% required a blood transfusion and 51.65% had a reduction in haemoglobin of more than 2 gm. The variable selection model identified 15 predictors associated with major bleeding. The discriminative ability of the model was good (c-statistic 0.75, p = 0.035). The Brier score of the model was 0.095. With a fixed cut-off probability value of 0.12 for the logistic regression equation, the sensitivity was 72.7%, and the specificity 66.3%.
This model demonstrated a good performance in predicting the bleeding risk in Arab patients treated with novel oral anticoagulants. This easy to use bleeding risk score will allow the clinician to quickly classify patients according to their risk category, supporting close monitoring and follow-up for high-risk patients, without laboratory and radiological monitoring.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0250502</identifier><identifier>PMID: 33939729</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Anticoagulants (Medicine) ; Atrial fibrillation ; Complications and side effects ; Dosage and administration ; Drug therapy ; Hemorrhage ; Medical research ; Medicine and Health Sciences ; Medicine, Experimental ; Risk factors</subject><ispartof>PloS one, 2021-05, Vol.16 (5), p.e0250502-e0250502</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 AlAmmari et al 2021 AlAmmari et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203</citedby><cites>FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203</cites><orcidid>0000-0002-8006-8544 ; 0000-0003-1828-0357</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092758/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092758/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33939729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nagler, Michael</contributor><creatorcontrib>AlAmmari, Maha</creatorcontrib><creatorcontrib>Sultana, Khizra</creatorcontrib><creatorcontrib>Alturaiki, Abdulrahman</creatorcontrib><creatorcontrib>Thomas, Abin</creatorcontrib><creatorcontrib>AlBabtain, Monirah</creatorcontrib><creatorcontrib>AlAyoubi, Fakahr</creatorcontrib><creatorcontrib>Richi, Hanie</creatorcontrib><title>The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example warfarin, in patients with non-valvular atrial fibrillation. Limited studies are available reporting a model with a good discriminative ability to predict the bleeding risk score when using direct oral anticoagulants.
Patient data were collected from King Abdulaziz Medical City, King Fahad Cardiac Center, and Prince Sultan Cardiac Center in Riyadh, from outpatients, inpatients, or primary care clinics. In total, 1722 patients with a prescription for a new oral anticoagulant, Dabigatran, Rivaroxaban, or Apixaban, were enrolled. A resampling approach for variable selection was used and a five-fold cross-validation to assess the model fit and misclassification probabilities. The analysis used the receiver operating characteristics curve (ROC) and the concordance (c) statistic to assess the validation models' discriminative power. The final penalized likelihood parameters were used for the development of the risk prediction tool. The accuracy of a classification and the prediction are reported with the sensitivity, specificity, and Brier score.
Bleeding occurred in 11.15% of cases, of which 23.08% required a blood transfusion and 51.65% had a reduction in haemoglobin of more than 2 gm. The variable selection model identified 15 predictors associated with major bleeding. The discriminative ability of the model was good (c-statistic 0.75, p = 0.035). The Brier score of the model was 0.095. With a fixed cut-off probability value of 0.12 for the logistic regression equation, the sensitivity was 72.7%, and the specificity 66.3%.
This model demonstrated a good performance in predicting the bleeding risk in Arab patients treated with novel oral anticoagulants. This easy to use bleeding risk score will allow the clinician to quickly classify patients according to their risk category, supporting close monitoring and follow-up for high-risk patients, without laboratory and radiological monitoring.</description><subject>Anticoagulants (Medicine)</subject><subject>Atrial fibrillation</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Hemorrhage</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Medicine, Experimental</subject><subject>Risk factors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqNk9-K1DAUxoso7rr6BiIBQfRixjRp2uZGWBb_LCws6OptOE2TmYxp0k3SUR_Q9zLdGZcZ8EJ60Sbn-345PeEriuclXpa0Kd9u_BQc2OXonVpiwjDD5EFxWnJKFjXB9OHB90nxJMYNxoy2df24OKGUU94Qflr8vlkr1Kutsn4clEsIXI-2YE0PyXiHvEaAhskms4VgoLMKDb5XFiWPxqB6IxNKGZELeeFWKJj4HUXpg0LaBzRmTMZG9MOkNXLeLTJ8O1kICFIGWqRNF4y1u-OmODN6E1Tm-pDL4JKRHlbZMmOMuzvuPECHRj9OO9_T4pEGG9Wz_fus-Prh_c3Fp8XV9cfLi_OrhawrnBatpMDriuuuLVnTtnXDaq4Za3pdQ61xp0rdY8Ykl7rRtKYKZEs5aSXDjcxzPCsud9zew0aMwQwQfgkPRtxt-LASEHK_VomeVLgiUjLOVMVlB20DvNWEAul6kFVmvduxxqkbVC_zlPL_HkGPK86sxcpvRYs5aVibAa_3gOBvJxWTGEyUKo_SKT9FQRghJWekabL05U66gtyacdpnopzl4ryuMaswb-eOlv9Q5adXQ74Dp7TJ-0eGN0eGrEnqZ1rBFKO4_PL5_7XX3461rw60awU2raO303zV8VhY7YQy-BiD0vfjK7GYUyL2KRFzSsQ-Jdn24nD096a_saB_AKM-FD4</recordid><startdate>20210503</startdate><enddate>20210503</enddate><creator>AlAmmari, Maha</creator><creator>Sultana, Khizra</creator><creator>Alturaiki, Abdulrahman</creator><creator>Thomas, Abin</creator><creator>AlBabtain, Monirah</creator><creator>AlAyoubi, Fakahr</creator><creator>Richi, Hanie</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8006-8544</orcidid><orcidid>https://orcid.org/0000-0003-1828-0357</orcidid></search><sort><creationdate>20210503</creationdate><title>The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population</title><author>AlAmmari, Maha ; Sultana, Khizra ; Alturaiki, Abdulrahman ; Thomas, Abin ; AlBabtain, Monirah ; AlAyoubi, Fakahr ; Richi, Hanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anticoagulants (Medicine)</topic><topic>Atrial fibrillation</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Hemorrhage</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Medicine, Experimental</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AlAmmari, Maha</creatorcontrib><creatorcontrib>Sultana, Khizra</creatorcontrib><creatorcontrib>Alturaiki, Abdulrahman</creatorcontrib><creatorcontrib>Thomas, Abin</creatorcontrib><creatorcontrib>AlBabtain, Monirah</creatorcontrib><creatorcontrib>AlAyoubi, Fakahr</creatorcontrib><creatorcontrib>Richi, Hanie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale in Context : Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJÂ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AlAmmari, Maha</au><au>Sultana, Khizra</au><au>Alturaiki, Abdulrahman</au><au>Thomas, Abin</au><au>AlBabtain, Monirah</au><au>AlAyoubi, Fakahr</au><au>Richi, Hanie</au><au>Nagler, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-05-03</date><risdate>2021</risdate><volume>16</volume><issue>5</issue><spage>e0250502</spage><epage>e0250502</epage><pages>e0250502-e0250502</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Frequently used models, such as the HAS-BLED, ATRIA, ORBIT, and GARFIELD-AF evaluate the risk of bleeding when using an anticoagulant, for example warfarin, in patients with non-valvular atrial fibrillation. Limited studies are available reporting a model with a good discriminative ability to predict the bleeding risk score when using direct oral anticoagulants.
Patient data were collected from King Abdulaziz Medical City, King Fahad Cardiac Center, and Prince Sultan Cardiac Center in Riyadh, from outpatients, inpatients, or primary care clinics. In total, 1722 patients with a prescription for a new oral anticoagulant, Dabigatran, Rivaroxaban, or Apixaban, were enrolled. A resampling approach for variable selection was used and a five-fold cross-validation to assess the model fit and misclassification probabilities. The analysis used the receiver operating characteristics curve (ROC) and the concordance (c) statistic to assess the validation models' discriminative power. The final penalized likelihood parameters were used for the development of the risk prediction tool. The accuracy of a classification and the prediction are reported with the sensitivity, specificity, and Brier score.
Bleeding occurred in 11.15% of cases, of which 23.08% required a blood transfusion and 51.65% had a reduction in haemoglobin of more than 2 gm. The variable selection model identified 15 predictors associated with major bleeding. The discriminative ability of the model was good (c-statistic 0.75, p = 0.035). The Brier score of the model was 0.095. With a fixed cut-off probability value of 0.12 for the logistic regression equation, the sensitivity was 72.7%, and the specificity 66.3%.
This model demonstrated a good performance in predicting the bleeding risk in Arab patients treated with novel oral anticoagulants. This easy to use bleeding risk score will allow the clinician to quickly classify patients according to their risk category, supporting close monitoring and follow-up for high-risk patients, without laboratory and radiological monitoring.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33939729</pmid><doi>10.1371/journal.pone.0250502</doi><tpages>e0250502</tpages><orcidid>https://orcid.org/0000-0002-8006-8544</orcidid><orcidid>https://orcid.org/0000-0003-1828-0357</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2021-05, Vol.16 (5), p.e0250502-e0250502 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d24042cc595e49cba87a98f23a2bdac4 |
source | Publicly Available Content Database; PubMed Central |
subjects | Anticoagulants (Medicine) Atrial fibrillation Complications and side effects Dosage and administration Drug therapy Hemorrhage Medical research Medicine and Health Sciences Medicine, Experimental Risk factors |
title | The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A33%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20development%20and%20validation%20of%20a%20multivariable%20model%20to%20predict%20the%20bleeding%20risk%20score%20for%20patients%20with%20non-valvular%20atrial%20fibrillation%20using%20direct%20oral%20anticoagulants%20in%20the%20Arab%20population&rft.jtitle=PloS%20one&rft.au=AlAmmari,%20Maha&rft.date=2021-05-03&rft.volume=16&rft.issue=5&rft.spage=e0250502&rft.epage=e0250502&rft.pages=e0250502-e0250502&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0250502&rft_dat=%3Cgale_doaj_%3EA660540984%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c640t-8c3a9649fb81578867569f557df6a6f0be1fd055c9cf7f363eac83928c507c203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2522195277&rft_id=info:pmid/33939729&rft_galeid=A660540984&rfr_iscdi=true |